HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-28-2008, 08:03 AM   #1
RobinP
Senior Member
 
RobinP's Avatar
 
Join Date: Nov 2005
Posts: 943
Chrisy, I think your question alone demonstrates that you are perhaps a propellarhead yourself. I think you know the answer to your question too. I want to confirm what your concerns are via the posted article that Rhonda so kindly posted above. The p185 surface area was reduced following tx. with OA. Now, Herceptin also decreases the p185 surface area receptor site. When Herceptin and OA are given together, there is according to this article a synergistic reaction where both work to decrease the receptor site of p185, thus decreasing heterodimerzation with other deleterious her family members, such as her1 and her3. As the p185 receptor site is blocked with the help of herceptin and OA, phosphorlazation and the downward PI3K pathway is block to prevent cellular proliferation. As you can see H. and OA are working together to prevent cellular replication. However, in your trail, you are counting on the Herceptin and cytoxic agent to destroy the her2 molecule, not prevent it from replication as the study Rhonda posted. Therefore, you need all the Herceptin and cytoxic agent you can get into the p185 site in order to destroy THE HER2 MOLECULE. NO, YOU DO NOT WANT OA, IN THIS CASE, TO COMPETE WITH THE P185 RECEPTOR SITE. YOU WANT ALL THE CYTOXIC AGENT CARRIED BY HERCEPTIN INTO THAT HER2 SITE WITHOUT THE COMPETING OA, OA DOES NOT CARRY THE CYTOXIC AGENT. I WOULD DEFINATELY CUT OUT ALL OA IN YOUR DIET. IN FACT, I AM SURPRISED THAT THE TRAIL DOES NOT SPECIFY OA RESTRICTION. I WOULD WRITE A LETTER TO THE INVESTIGATORS ABOUT YOUR CONCERNS OVER OA.

RESULTS: Flow cytometric analyses demonstrated a dramatic (up to 46%) reduction of cell surface-associated p185(Her-2/neu) following treatment of the Her-2/neu-overexpressors BT-474 and SK-Br3 with OA. Indeed, this effect was comparable to that found following exposure to optimal concentrations of trastuzumab (up to 48% reduction with 20 microg/ml trastuzumab). Remarkably, the concurrent exposure to OA and suboptimal concentrations of trastuzumab (5 microg/ml) synergistically down-regulated Her-2/neu expression, as determined by flow cytometry (up to 70% reduction), immunoblotting, and immunofluorescence microscopy studies. The nature of the cytotoxic interaction between OA and trastuzumab revealed a strong synergism, as assessed by MTT-based cell viability and anchorage-independent soft-agar colony formation assays.
__________________
Robin
2002- dx her2 positive DCIS/bc TX Mast, herceptin chemo
RobinP is offline   Reply With Quote
Old 01-28-2008, 09:43 AM   #2
chrisy
Senior Member
 
chrisy's Avatar
 
Join Date: Sep 2005
Location: Central Coast, CA
Posts: 3,207
Propellerhead? Moi?

Robin,
You restated my concerns EXACTLY, only it sounded much more impressive and scientific! At best, I'm an illiterate propellerhead! Maybe we can go into business together translating this stuff between "english" and "science".

You come to the same opinion I did, and I will definitely pose this question.

Lily - let me know what you find out on your end, it's an interesting question, isn't it? On the other hand, you are clearly doing very well on this drug, so by the "proof is in the pudding" standard it seems not to be hurting.

Brenda, I think you should be ok on the EVOO since for you reducing the amount of Her2 would still be a good thing. In fact, you could probably have my share, too! Ever chug a bottle of EVOO???

If I were to predict, I would guess that the doc's answer will be to avoid ingesting excessive amounts of oleic acid. But unfortunately I doubt the recommendation will be to go back to eating butter!

Hoping to hear some more people weigh in on this...
__________________
Chris in Scotts Valley
June 2002 extensive hi grade DCIS (pre-cancer-stage 0, clean sentinal node) Mastectomy/implant - no chemo, rads. "cured?"
9/2004 Diag: Stage IV extensive liver mets (!) ER/PR- Her2+++
10/04-3/05 Weekly Taxol/Carboplatin/Herceptin , complete response!
04/05 - 4/07 Herception every 3 wks, Continue NED
04/07 - recurrence to liver - 2 spots, starting tykerb/avastin trial
06/07 8/07 10/07 Scans show stable, continue on Tykerb/Avastin
01/08 Progression in liver
02/08 Begin (TDM1) trial
08/08 NED! It's Working! Continue on TDM1
02/09 Continue NED
02/10 Continue NED. 5/10 9/10 Scans NED 10/10 Scans NED
12/10 Scans not clear....4/11 Scans suggest progression 6/11 progression confirmed in liver
07/11 - 11/11 Herceptin/Xeloda -not working:(
12/11 Begin MM302 Phase I trial - bust:(
03/12 3rd times the charm? AKT trial

5/12 Scan shows reduction! 7/12 More reduction!!!!
8/12 Whoops...progression...trying for Perjeta/Herceptin (plus some more nasty chemo!)
9/12 Start Perjeta/Herceptin, chemo on hold due to infection/wound in leg, added on cycle 2 &3
11/12 Poops! progression in liver, Stop Perjeta/Taxo/Herc
11/12 Navelbine/Herce[ptin - try for a 3 cycles, no go.
2/13 Gemzar/Carbo/Herceptin - no go.
3/13 TACE procedure
chrisy is offline   Reply With Quote
Old 01-28-2008, 11:13 AM   #3
Lolly
Senior Member
 
Lolly's Avatar
 
Join Date: Aug 2001
Location: Oregon
Posts: 1,756
This is an interesting thread. I've been wondering about this myself, only didn't quite know how to form the question coherently, so thanks Chris for bringing it up, it's really "food for thought".

<3 Lolly
__________________
Sept.'99 - Dx.Stage IIIB, IDC ER/PR-, HER2+++ by IHC, confirmed '04 by FISH. Left MRM, AC x's 4, Taxol x's 4, 33 Rads, finishing Tx May 2000. Jan.'01 - local/regional recurrence, Stage IV. Herceptin/Navelbine weekly till NED August 2001, then maintenance Herceptin. Right Mast. April 2002. Local/Regional recurrence April '04, Herceptin plus/minus chemo until May '07. Gemzar added from Feb.'07-April '07; Tykerb/Abraxane until August '07, back on Herceptin plus Taxotere and Xeloda Sept. '07. Stopped T/X Nov. '07, stopped Herceptin Dec. '07, started Avastin/Taxol/Carboplatin Dec. '07. Progression in chest skin, stopped TAC March '03, started radiation.

Herceptin has served as the "Backbone" of my treatment strategy for over 6 years, giving me great quality of life. In 2005, I was privileged to participate in the University of Washington/Seattle HER2 Vaccine Trial.
Lolly is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 09:30 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter